Form 4: Myriad Genetics Director Colleen Reitan Receives Significant Equity Grant

Myriad Genetics Inc. Director Colleen F. Reitan was granted 49,796 restricted stock units, increasing her beneficial ownership to 92,329 shares.

Summary

• Colleen F. Reitan, a Director of Myriad Genetics Inc. (MYGN), acquired 49,796 shares of common stock on June 5, 2025.
• The acquisition was in the form of restricted stock units (RSUs) granted under Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended.
• Each RSU represents a contingent right to receive one share of common stock and was granted at a price of $0.
• Following this transaction, Ms. Reitan's total beneficial ownership of Myriad Genetics common stock increased to 92,329 shares.
• The RSUs are set to vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates a routine equity grant to a director, aligning their interests with shareholders and demonstrating commitment to the company's long-term performance. It's a standard compensation practice.

Positives

• The grant of restricted stock units to a director aligns their interests with those of the shareholders, incentivizing long-term performance.
• The equity incentive plan provides a mechanism for attracting and retaining qualified directors and employees.

Future Outlook

The restricted stock units granted to Director Colleen F. Reitan are scheduled to vest upon the earlier of the first anniversary of the grant date (June 5, 2026) or the date of the next annual meeting of stockholders following the grant, indicating future share issuance upon vesting.

Industry Context

The granting of restricted stock units to directors is a common practice across various industries, including biotechnology and diagnostics, serving as a standard component of executive and director compensation packages to align leadership incentives with company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a form of director compensation is a widely adopted practice, comparable to compensation structures at companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH) in the diagnostics sector, which also utilize equity grants to incentivize their leadership.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is a standard approach for director equity grants, ensuring continued engagement and oversight.

Related Party Transactions

• The grant of restricted stock units to Colleen F. Reitan, a Director, constitutes a transaction with a related party, executed under the company's established equity incentive plan.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the value of the RSUs is tied to the company's stock performance.
• Director (Colleen F. Reitan): Receives equity compensation, incentivizing her continued service and contribution to the company's success.

Next Steps

• The restricted stock units will vest upon the earlier of June 5, 2026, or the date of the next annual meeting of stockholders following the grant.

Key Dates

Recommendation

Keywords

Myriad Genetics, MYGN, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Stock Ownership